9 completed, 1 terminated. 4 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow MC2 Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects MC2-01 cream, MC2-01 vehicle, CAL/BDP Gel - Plaque Psoriasis | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 539 | 2025-12-30 | 2026-08-28 |
| Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) MC2-25 cream, MC2-25 vehicle - Vulvar Lichen Sclerosus | Phase 2 | Completed | MC2 Therapeutics | 33 | 2023-10-11 | 2025-10-15 |
| The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial MC2-25 cream, MC2-25 vehicle - Chronic Kidney Disease-associated Pruritus | Phase 2 | Completed | MC2 Therapeutics | 111 | 2022-07-01 | 2025-03-17 |
| Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation - Phototoxicity | Phase 1 | Completed | MC2 Therapeutics | 35 | 2019-02-27 | 2020-02-12 |
| Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation - Photoallergy | Phase 1 | Completed | MC2 Therapeutics | 58 | 2019-02-13 | 2020-03-11 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects MC2-01 cream - Psoriasis Vulgaris | Phase 2 | Terminated | MC2 Therapeutics | 7 | 2018-12-27 | 2021-03-19 |
| This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream MC2-01 cream, Cal/BDP combination, Vehicle - Psoriasis Vulgaris | Phase 3 | Completed | MC2 Therapeutics | 498 | 2018-12-12 | 2020-12-16 |
| Evaluation of the Vasoconstriction Properties of MC2-01 Cream MC2-01 Cream, Clobetasol Propionate 0.05% Lotion, Betamethasone Dipropionate 0.05% Cream - Vasoconstriction | Phase 1 | Completed | MC2 Therapeutics | 36 | 2018-11-05 | 2020-01-09 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream MC2-01 Cream, CAL/BDP combination - Psoriasis Vulgaris | Phase 2 | Completed | MC2 Therapeutics | 63 | 2018-02-08 | 2019-12-24 |
| A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream MC2-01 cream, Cal/BDP combination, Cream vehicle - Psoriasis Vulgaris | Phase 3 | Completed | MC2 Therapeutics | 794 | 2017-10-03 | 2024-12-09 |
Dermatitis, Photoallergic (1) · Dermatitis, Phototoxic (1) · Vulvar Lichen Sclerosus (1)
Radiation (2) · Clobetasol (1) · Desonide (1) · Triamcinolone Acetonide (1) · betamethasone-17,21-dipropionate (1) · calcipotriene (1) · hydrocortisone-17-butyrate (1)
United States (4) · Czechia (2) · Germany (2) · China (1) · Denmark (1) · France (1) · United Kingdom (1)
Andreas Pinter, MD (1) · George Han (1) · Jonathan S Dorsik (1) · Jonathan S Dosik, MD (1) · Linda S. Gold, MD (1)
PMID 37490268, PMID 40274711, PMID 33852251, PMID 34648147, PMID 36050567